Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbot Medical ( (MBOT) ) has provided an announcement.
On April 14, 2026, Microbot Medical announced it would showcase recent commercial milestones that led to the Full Market Release of its LIBERTY Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference, held April 13-16, 2026. CEO Harel Gadot and senior executives planned a live presentation on April 15, 2026, outlining the company’s strategic positioning, growth opportunities and its role in addressing physician radiation risks, physical strain and staffing shortages.
The company noted that LIBERTY, which recently completed a limited U.S. market release before entering full market release earlier that week at the Society of Interventional Radiology Annual Scientific Meeting, is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot also arranged one-on-one meetings with healthcare-focused institutional investors, underscoring rising engagement with healthcare institutions and signaling building commercial momentum around its endovascular robotics platform.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the world’s first FDA-cleared, single-use, remotely operated robotic solution designed to enhance precision, efficiency and safety in peripheral endovascular interventions.
Backed by a substantial intellectual property portfolio, Microbot Medical targets markets with unmet needs such as reducing physician radiation exposure, physical strain and staffing challenges. The company positions itself as a driver of the future of endovascular care, aiming to broaden adoption of robotic systems across healthcare institutions in the U.S. and beyond.
Average Trading Volume: 2,080,498
Technical Sentiment Signal: Buy
Current Market Cap: $173.9M
Learn more about MBOT stock on TipRanks’ Stock Analysis page.